Visitors to the upcoming BIO International Convention in San Diego will have the opportunity to explore how key players in the industry are tackling the challenges of personalized genetic medicines. The hour-long session, hosted by Precision NanoSystems and moderated by the company’s COO and co-founder Euan Ramsay, will be held on June 22nd, from 9am, at the San Diego Convention Center, RM 6C. Speakers have been chosen for their specific focus in different stages of the clinical development process, and will talk about the challenges and possible solutions for genetic medicine development.

Arthur Tzianabos from Homology Medicines will begin the session by looking at genome editing from a viral vector perspective. Intellia’s Thomas Barnes will then discuss the company’s CRISPR/Cas9 genome editing technology, outlining how different drug delivery technologies may be suitable for different diseases. This will be followed by an explanation of how Gritstone Oncology is combining technologies to deliver personalized cancer vaccines from the company’s Karin Jooss. And finally, the audience will hear from Melinda Griffith from the Parker Institute, who will be describing the first CRISPR/Cas9 trial in the United States, and the regulatory and ethical challenges it has raised. The floor will then be opened up for a Q&A session with the panel.

Moderator Euan Ramsay said: "Precision NanoSystems is delighted to be organizing this exciting session, providing an exclusive opportunity to bring leading lights from across this fast-growing sector together to discuss the latest developments. We are very grateful to all of our speakers for agreeing to participate, and look forward to their presentations."